Loading...
NPI 1598770471 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Allison Curtis Kingsley Meoz Michael & Sanchez PC is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 0 Medicare and 92 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Allison Curtis Kingsley Meoz Michael & Sanchez PC |
| Address | 3730 S Eastern Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89169 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | July 29, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $13.4M |
| Medicare | $0 |
This entity has no Medicare billing on file and is effectively a single-payer Medicaid billing operation, with Total Medicaid revenue reported at $13.4M. The absence of Medicare revenue means analyses should be framed around Medicaid activity and state-level competitive dynamics rather than cross-payer comparisons.
Revenue concentration is high: the precomputed top 3 Medicaid codes account for 56.3% of the provider's total Medicaid revenue, indicating the practice’s income is driven by a small set of services rather than a broad mix of low-revenue items. That level of concentration suggests operational focus around specific oncology and office-based E/M services.
The largest single Medicaid revenue contributor is 99214, producing $3.9M and representing 30.0% of Medicaid revenue; the provider ranks #9 of 2254 in-state and is labeled an "extreme outlier, far above typical state volume for this code." This indicates the provider delivers a very high volume of established outpatient E/M visits relative to peers, consistent with a high-throughput clinic model.
Chemotherapy administration code 96413 is the second-largest revenue driver with $1.7M (13.6% of Medicaid revenue) and the provider ranks #1 of 19 in-state for this code, again an "extreme outlier, far above typical state volume." High volumes of 96413 together with E/M codes point to integrated oncology services delivering frequent IV chemotherapy sessions as a core service line.
99213 is another major contributor at $1.6M (12.7% of Medicaid revenue) and ranks #28 of 2476 in-state, also characterized as an "extreme outlier, far above typical state volume for this code." The combined prominence of 99213 and 99214 underscores that office-based evaluation and management visits form a substantial portion of billed activity and revenue.
Several supportive infusion, antiemetic, and biologic drug codes also appear among top-revenue items, including 96375 ($530.2K), J2469 ($405.6K), and Q0138 ($430.6K). Multiple drug/infusion codes rank at or near #1 in-state for their respective descriptors, which reinforces that the practice operates a high-volume infusion service line alongside oncologic care.
Procedural oncology and radiation-therapy related codes such as G6015 ($541.2K) and 77427 ($99.9K) are present and, for G6015, the provider ranks #1 of 3 in-state; this suggests the organization offers advanced radiation or treatment-delivery modalities in addition to systemic therapy, broadening its cancer-treatment mix.
The provider’s NPI has been enumerated since 2006-07-29 (~20 years ago), indicating long tenure in the market. Combined with top-state rankings for multiple high-volume Medicaid codes, this longevity supports a picture of an established oncology practice with deep Medicaid patient flow in Nevada.
Across many codes the provider is flagged as an extreme outlier or notably above typical state volume (for example 99214, 96413, 99213, 99215), signaling market dominance in certain service lines at the state level. For payer or network strategy, this combination of high case volumes in E/M and chemotherapy-administration codes makes the provider a major Medicaid oncology care site in Nevada and a potential focal point for Medicaid oncology contracting and utilization-management initiatives.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
92 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 62,130 | $60 | $3.9M |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 22,900 | $80 | $1.7M |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 36,120 | $50 | $1.6M |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 24,540 | $30 | $638K |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 1,980 | $270 | $541.1K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 33,140 | $20 | $530.2K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 690 | $620 | $430.6K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 5,630 | $70 | $405.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 5,490 | $70 | $384.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 7,970 | $40 | $318.7K |
Showing 1–10 of 92
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
92 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 1 | 10 | 690 | $620 | $430.2K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 90 | 470 | 380 | $70 | $281.2K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1 | 10 | 170 | $1,570 | $262.4K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 30 | 430 | 500 | $40 | $214.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 1 | 20 | 240 | $90 | $189.3K |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 1 | 10 | 100 | $260 | $186.5K |
| 96374 | The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition. | 43 | 80 | 2,150 | $20 | $183.5K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 72 | 430 | 180 | $130 | $158K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1 | 10 | 150 | $70 | $140.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 9 | 2,250 | 290 | $60 | $138K |
Showing 1–10 of 92
Other providers in the same ZIP code as Allison Curtis Kingsley Meoz Michael & Sanchez PC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.